Lao PDR: Filgotinib Has Been Launched

Lao PDR: Filgotinib Has Been Launched

Before initiating filgotinib treatment, strict screening for the following contraindications is mandatory; the presence of any one of these conditions precludes its use. First, hypersensitivity to filgotinib or any of its excipients (such as lactose, microcrystalline cellulose, iron oxide pigments, etc.), which may cause severe anaphylactic reactions. Second, active tuberculosis, because JAK inhibitors may impair the host immune control against Mycobacterium tuberculosis, potentially leading to disseminated infection. Third, active serious infections, such as sepsis, invasive fungal infections, or opportunistic infections, where immunosuppression would exacerbate the condition. Fourth, pregnancy or suspected pregnancy, as animal studies suggest possible embryotoxicity and human safety data are insufficient. If you meet any of the above criteria, inform your physician immediately and do not take the medication on your own. In addition, even if not contraindicated, if you have a history of chronic infection, malignancy, or coagulation abnormalities, a specialist evaluation is required before making a decision. Your doctor will weigh the risks and benefits based on your complete medical history, physical examination, and laboratory results (including tuberculosis screening, hepatitis viral markers, complete blood count, and liver/kidney function) to ensure medication safety.

Filgotinib: Infection Risk and Monitoring Points

Filgotinib can reduce the body's ability to defend against pathogenic microorganisms; therefore, infection is the most important adverse event to watch for during treatment. You should proactively report any signs of infection to your doctor, such as fever, chills, persistent cough, sore throat, urinary discomfort, wound redness, or unusual fatigue. If you have a history of recurrent infections, diabetes (poor glycemic control predisposes to infection), or are aged ≥65 years, the infection risk is further increased. Tuberculosis screening (e.g., T‑SPOT or PPD test) must be performed before treatment; those with latent tuberculosis should receive standard anti-tuberculosis prophylaxis first. Regular re‑testing during treatment is also recommended, especially when respiratory symptoms appear. For patients with a history of herpes zoster, filgotinib may reactivate the latent virus; if unilateral vesicular rash with neuralgia occurs, seek medical attention immediately. Moreover, if a serious infection develops, your doctor may temporarily suspend the drug until the infection is fully controlled. It is advised that you strengthen personal hygiene, avoid contact with infectious sources, and complete the recommended monitoring items on time, including complete blood count, C‑reactive protein, and liver/kidney function tests, to allow timely adjustment of treatment strategy.

How Serious Are the Side Effects of Filgotinib?

Tuberculosis is the most specific infection associated with filgotinib, as it can present either as primary active disease or reactivation of latent infection. All patients must undergo a detailed tuberculosis assessment before medication, including symptom enquiry (chronic cough, afternoon low‑grade fever, night sweats, weight loss), imaging studies, and immunological tests. Those who have had close contact with active tuberculosis patients or who were born in high‑prevalence areas require intensified screening. For latent infection, at least 1 month of anti‑tuberculosis preventive therapy should be completed before starting filgotinib. Herpes zoster (varicella‑zoster virus reactivation) occurred at a rate of about 1% in clinical trials, presenting as painful clustered vesicles on the trunk or face; involvement of the eye or ear requires emergency management. Meanwhile, patients with hepatitis B or C virus infection need viral load and liver function testing, because immune modulation may accelerate viral replication and even lead to fulminant hepatitis. For those who are HBsAg‑positive or anti‑HBc‑positive, prophylactic antiviral therapy is recommended. These screenings are not limited to baseline; they should also be repeated regularly during long‑term maintenance therapy, especially when corresponding symptoms or laboratory abnormalities appear.